Article

FDA approves trypan blue 0.15%

The FDA has approved trypan blue ophthalmic solution 0.15% (MembraneBlue, Dutch Ophthalmic Research Center International, b.v.) for use as an aid during vitrectomy procedures by staining the epiretinal membranes and, thereby, facilitating the removal of tissue, according to a prepared statement.

Exeter, NH

―The FDA has approved trypan blue ophthalmic solution 0.15% (MembraneBlue, Dutch Ophthalmic Research Center International, b.v.) for use as an aid during vitrectomy procedures by staining the epiretinal membranes and, thereby, facilitating the removal of tissue, according to a prepared statement.

Available in sterile, single-use, 2.25-ml syringes filled to a volume of 0.5 ml, trypan blue 0.15% is the first and only approved solution for this indication, the company said. It selectively stains epiretinal membranes during ophthalmic surgical vitrectomy procedures and is intended to be applied directly to areas where membranes could be present.

Previously, trypan blue ophthalmic solution 0.06% (VisionBlue) was the only stain approved by the FDA for the anterior capsule of the lens during capsulorhexis. According to the statement, with this new FDA approval, trypan blue 0.15% now provides vitreoretinal surgeons with a higher concentration of a sterile solution of the acid diazo group dye.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.